Congenital segmental lymphedema in tuberous sclerosis complex with associated subependymal giant cell astrocytomas treated with mammalian target of rapamycin inhibitors

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Tuberous sclerosis complex is a genetic, multisystemic disorder characterized by circumscribed benign lesions (hamartomas) in several organs, including brain. This is the result of defects in the TSC1 and/or TSC2 tumor suppressor genes, encoding the hamartin-tuberin complex that inhibits the mammalian target of rapamycin pathway. Specific inhibitors of this pathway have been shown to reduce the volume of subependymal giant cell astrocytomas associated with tuberous sclerosis. Congenital lymphedema is rarely seen in association with tuberous sclerosis, with only a few reported cases. Although this association can be coincidental, the dysgenetic lymphatic system can represent a hamartia as a consequence of gene mutation. We describe a child with congenital lymphedema in tuberous sclerosis and associated subependymal giant cell astrocytoma who experienced lymphangitis under treatment with mammalian target of rapamycin inhibitors. Because our patient did not show worsening of lymphedema, congenital lymphedema does not seem to be a contraindication for this therapy.

Original languageEnglish
Pages (from-to)NP54-NP57
JournalJournal of Child Neurology
Volume29
Issue number9
DOIs
Publication statusPublished - 2014

Fingerprint

Tuberous Sclerosis
Lymphedema
Astrocytoma
Sirolimus
Lymphangitis
Lymphatic System
Inborn Genetic Diseases
Hamartoma
Tumor Suppressor Genes
Mutation
Brain
Therapeutics
Genes

Keywords

  • Congenital lymphedema
  • Mammalian target of rapamycin inhibitors
  • Tuberous sclerosis complex

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Medicine(all)

Cite this

@article{9ffe33daf73e4e84ad9ae4ba89a2fa32,
title = "Congenital segmental lymphedema in tuberous sclerosis complex with associated subependymal giant cell astrocytomas treated with mammalian target of rapamycin inhibitors",
abstract = "Tuberous sclerosis complex is a genetic, multisystemic disorder characterized by circumscribed benign lesions (hamartomas) in several organs, including brain. This is the result of defects in the TSC1 and/or TSC2 tumor suppressor genes, encoding the hamartin-tuberin complex that inhibits the mammalian target of rapamycin pathway. Specific inhibitors of this pathway have been shown to reduce the volume of subependymal giant cell astrocytomas associated with tuberous sclerosis. Congenital lymphedema is rarely seen in association with tuberous sclerosis, with only a few reported cases. Although this association can be coincidental, the dysgenetic lymphatic system can represent a hamartia as a consequence of gene mutation. We describe a child with congenital lymphedema in tuberous sclerosis and associated subependymal giant cell astrocytoma who experienced lymphangitis under treatment with mammalian target of rapamycin inhibitors. Because our patient did not show worsening of lymphedema, congenital lymphedema does not seem to be a contraindication for this therapy.",
keywords = "Congenital lymphedema, Mammalian target of rapamycin inhibitors, Tuberous sclerosis complex",
author = "Giulia Prato and Mancardi, {Maria Margherita} and Baglietto, {Maria Giuseppina} and Sara Janis and Nadia Vercellino and Andrea Rossi and Alessandro Consales and Alessandro Raso and Garr{\`e}, {Maria Luisa}",
year = "2014",
doi = "10.1177/0883073813499969",
language = "English",
volume = "29",
pages = "NP54--NP57",
journal = "Journal of Child Neurology",
issn = "0883-0738",
publisher = "SAGE Publications Inc.",
number = "9",

}

TY - JOUR

T1 - Congenital segmental lymphedema in tuberous sclerosis complex with associated subependymal giant cell astrocytomas treated with mammalian target of rapamycin inhibitors

AU - Prato, Giulia

AU - Mancardi, Maria Margherita

AU - Baglietto, Maria Giuseppina

AU - Janis, Sara

AU - Vercellino, Nadia

AU - Rossi, Andrea

AU - Consales, Alessandro

AU - Raso, Alessandro

AU - Garrè, Maria Luisa

PY - 2014

Y1 - 2014

N2 - Tuberous sclerosis complex is a genetic, multisystemic disorder characterized by circumscribed benign lesions (hamartomas) in several organs, including brain. This is the result of defects in the TSC1 and/or TSC2 tumor suppressor genes, encoding the hamartin-tuberin complex that inhibits the mammalian target of rapamycin pathway. Specific inhibitors of this pathway have been shown to reduce the volume of subependymal giant cell astrocytomas associated with tuberous sclerosis. Congenital lymphedema is rarely seen in association with tuberous sclerosis, with only a few reported cases. Although this association can be coincidental, the dysgenetic lymphatic system can represent a hamartia as a consequence of gene mutation. We describe a child with congenital lymphedema in tuberous sclerosis and associated subependymal giant cell astrocytoma who experienced lymphangitis under treatment with mammalian target of rapamycin inhibitors. Because our patient did not show worsening of lymphedema, congenital lymphedema does not seem to be a contraindication for this therapy.

AB - Tuberous sclerosis complex is a genetic, multisystemic disorder characterized by circumscribed benign lesions (hamartomas) in several organs, including brain. This is the result of defects in the TSC1 and/or TSC2 tumor suppressor genes, encoding the hamartin-tuberin complex that inhibits the mammalian target of rapamycin pathway. Specific inhibitors of this pathway have been shown to reduce the volume of subependymal giant cell astrocytomas associated with tuberous sclerosis. Congenital lymphedema is rarely seen in association with tuberous sclerosis, with only a few reported cases. Although this association can be coincidental, the dysgenetic lymphatic system can represent a hamartia as a consequence of gene mutation. We describe a child with congenital lymphedema in tuberous sclerosis and associated subependymal giant cell astrocytoma who experienced lymphangitis under treatment with mammalian target of rapamycin inhibitors. Because our patient did not show worsening of lymphedema, congenital lymphedema does not seem to be a contraindication for this therapy.

KW - Congenital lymphedema

KW - Mammalian target of rapamycin inhibitors

KW - Tuberous sclerosis complex

UR - http://www.scopus.com/inward/record.url?scp=84927763706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927763706&partnerID=8YFLogxK

U2 - 10.1177/0883073813499969

DO - 10.1177/0883073813499969

M3 - Article

C2 - 24056156

AN - SCOPUS:84927763706

VL - 29

SP - NP54-NP57

JO - Journal of Child Neurology

JF - Journal of Child Neurology

SN - 0883-0738

IS - 9

ER -